Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CalciMedica ( (CALC) ) has shared an announcement.
On March 4, 2025, CalciMedica announced new data from a post-hoc analysis of the Phase 2 CARDEA trial, highlighting Auxora’s potential in reducing mortality among patients with severe COVID-19 pneumonia and acute kidney injury (AKI). The analysis revealed a 62.7% relative reduction in mortality for Auxora-treated patients compared to placebo, indicating a significant therapeutic benefit. This data underscores the potential of CRAC channel inhibition in treating AKI and supports ongoing clinical trials, which may enhance CalciMedica’s positioning in the biopharmaceutical industry.
More about CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The company’s lead product candidate, Auxora, has shown positive results in multiple clinical trials, targeting acute and chronic inflammatory conditions.
YTD Price Performance: -32.52%
Average Trading Volume: 41,036
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $29.93M
For an in-depth examination of CALC stock, go to TipRanks’ Stock Analysis page.